Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 19.38% is 172% above its 5-year average of -27.00%, near the high end of its 5-year range (-136.29%–28.91%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.10% below its 12-month average of 24.25%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 19.38%.
RETURN ON EQUITY (ROE)
19.38%
RETURN ON EQUITY (ROE) AVG TTM
24.25%
RETURN ON EQUITY (ROE) AVG 3Y
6.77%
RETURN ON EQUITY (ROE) AVG 5Y
-27.00%
RETURN ON EQUITY (ROE) AVG 10Y
-56.07%
RETURN ON EQUITY (ROE) AVG 15Y
-74.89%
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-20.10%
CURRENT VS 3Y AVG
+186.10%
CURRENT VS 5Y AVG
+171.76%
CURRENT VS 10Y AVG
+134.56%
CURRENT VS 15Y AVG
+125.87%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+146.12%
vs the sector median at left
Niagen Bioscience Inc
Market Cap
$214.24M
Return on Equity (ROE)
19.38%
TTM Avg
24.25%
3Y Avg
6.77%
5Y Avg
-27.00%
Market Cap
$214.46M
Return on Equity (ROE)
-36.64%
TTM Avg
6.57%
3Y Avg
27.96%
5Y Avg
27.96%
Market Cap
$215.07M
Return on Equity (ROE)
21.24%
TTM Avg
17.52%
3Y Avg
32.51%
5Y Avg
46.01%
Market Cap
$216.91M
Return on Equity (ROE)
-45.23%
TTM Avg
-120.85%
3Y Avg
-88.04%
5Y Avg
-69.68%
Market Cap
$210.98M
Return on Equity (ROE)
-106.27%
TTM Avg
-100.08%
3Y Avg
-64.49%
5Y Avg
-52.22%
Market Cap
$210.41M
Return on Equity (ROE)
-71.02%
TTM Avg
-15.82%
3Y Avg
-19.73%
5Y Avg
-5.35%
Market Cap
$218.30M
Return on Equity (ROE)
-31.70%
TTM Avg
-2.04%
3Y Avg
-21.96%
5Y Avg
-21.56%
Market Cap
$209.91M
Return on Equity (ROE)
39.66%
TTM Avg
4.24%
3Y Avg
-15.88%
5Y Avg
-20.06%
Market Cap
$208.31M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Niagen Bioscience Inc (NAGE) | $214.24M | 19.38% | 24.25% | 6.77% | -27.00% |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | -36.64% | 6.57% | 27.96% | 27.96% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 21.24% | 17.52% | 32.51% | 46.01% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | -45.23% | -120.85% | -88.04% | -69.68% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -106.27% | -100.08% | -64.49% | -52.22% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | -71.02% | -15.82% | -19.73% | -5.35% |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | -31.70% | -2.04% | -21.96% | -21.56% |
| Compugen Ltd. (CGEN)vs › | $209.91M | 39.66% | 4.24% | -15.88% | -20.06% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | -65.59% | -45.72% | -59.51% | -49.73% |
ROE
19.4%
ROA
15.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 19.38% |
| 2026-03-31 | 22.64% |
| 2025-12-31 | 22.71% |
| 2025-09-30 | 28.91% |
| 2025-06-30 | 27.62% |
| 2025-03-31 | 25.49% |
| 2024-12-31 | 18.55% |
| 2024-09-30 | 4.32% |
| 2024-06-30 | -4.40% |
| 2024-03-31 | -12.19% |
| 2023-12-31 | -17.35% |
| 2023-09-30 | -23.69% |
| 2023-06-30 | -23.93% |
| 2023-03-31 | -38.20% |
| 2022-12-31 | -57.69% |
| 2022-09-30 | -97.26% |
| 2022-06-30 | -136.29% |
| 2022-03-31 | -106.22% |
| 2021-12-31 | -85.50% |
| 2021-09-30 | -78.70% |
| 2021-06-30 | -55.19% |
| 2021-03-31 | -48.83% |
| 2020-12-31 | -121.32% |
| 2020-09-30 | -116.39% |
| 2020-06-30 | -118.94% |
| 2020-03-31 | -179.55% |
| 2019-12-31 | -157.24% |
| 2019-09-30 | -116.10% |
| 2019-06-30 | -217.33% |
| 2019-03-31 | -158.32% |
| 2018-12-31 | -122.58% |
| 2018-09-30 | -101.55% |
| 2018-06-30 | -57.23% |
| 2018-03-31 | -38.34% |
| 2017-12-31 | -21.14% |
| 2017-09-30 | -13.94% |
| 2017-06-30 | -30.30% |
| 2017-03-31 | -54.55% |
| 2016-12-31 | -29.36% |
| 2016-09-30 | -18.62% |
| 2016-06-30 | -10.10% |
| 2016-03-31 | -23.18% |
| 2015-12-31 | -52.54% |
| 2015-09-30 | -59.32% |
| 2015-06-30 | -82.84% |
| 2015-03-31 | -123.77% |
| 2014-12-31 | -134.76% |
| 2014-09-30 | -108.48% |
| 2014-06-30 | -126.80% |
| 2014-03-31 | -101.02% |
| 2013-12-31 | -78.01% |
| 2013-09-30 | -165.01% |
| 2013-06-30 | -79.00% |
| 2013-03-31 | -128.52% |
| 2012-12-31 | -292.05% |
| 2012-09-30 | -238.19% |
| 2012-06-30 | -237.74% |
| 2012-03-31 | -135.14% |
| 2011-12-31 | -308.24% |
| 2011-09-30 | -138.42% |
| 2011-06-30 | -106.78% |
| 2011-03-31 | -64.63% |
| 2010-12-31 | -41.56% |
| 2010-09-30 | -24.72% |
| 2010-06-30 | -10.08% |
| 2010-03-31 | -48.55% |
| 2009-12-31 | -86.65% |
| 2009-09-30 | -129.86% |
| 2009-06-30 | -160.29% |
| 2009-03-31 | -156.59% |
